EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 18 April 2024

News

Patient Information Leaflets: Putting Patients First
17 April 2024

AESGP, EFPIA and Medicines for Europe publish joint recommendations for better patient information leaflets Read more

Rare Disease Moonshot: breaking down barriers to accelerate research

The Rare Disease (RD) Moonshot was set up to boost public private collaborations in the areas where there are no treatment options and there is no R&D going on.

The RD Moonshot partners put together three sets of recommendations to highlight where public-private collaborations can add most value.

Click here to learn more on the recommendations to optimise clinical trials for rare disease.

Is Europe on track to be a world leader in rare diseases?

36 million Europeans live with a rare disease. The EU needs to scale up and improve the patient journey and diagnosis, which is different from a member state to another.  

Watch the full recording of the POLITICO webinar here.

Events

Data driven life course immunisation : What are we waiting for?
23 April 2024 (Hybrid - Edegem and Online)

A hybrid event uncovering what is needed to leverage the full potential of health data toward life course immunisation... Read more

12th European Conference on Rare Disease & Orphan Products
15 May 2024 (Hybrid - Brussels and Online)

The ECRD is the largest, patient-led, rare disease policy-shaping event held in Europe. Read more

What we are reading

"Unbalanced" EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
On 16 April 2024 (Pink Sheet)

As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments... Read more

Staying ahead: the case for a European Action Plan for Rare Diseases
On 16 April 2024 (Global Counsel)

This report and its accompanying event, “Rare Diseases Forum 2024: Securing Europe’s competitiveness in R&D for... Read more

Socio-Economic Value of Adult Immunisation Programmes
On 18 April 2024 (OHE)

Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond... Read more

The EU General Pharmaceutical Legislation & Clawbacks: Calculated impacts – both designed and...
On 18 April 2024 (Vital Transformation)

The European Commission has proposed that the revised General Pharmaceutical Legislation will replace the current... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu